Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone vs Metformin for Cardiovascular Outcomes in Type 2 Diabetes
NCT00399204Phase 4Withdrawn
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Jan 2006
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of pioglitazone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoints: Cardiovascular Morbidity and Cardiovascular Mortality. Planned start Jan 2006; status: withdrawn.
02
Drugs
pioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00399204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00399204.